Health Dictionary Find a Doctor

Seminoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Surgery is the mainstay of treatment for seminoma. The feasibility of surgery depends on the stage of seminoma at diagnosis which include: radical inguinal orchiectomy, retroperitoneal lymph node dissection, salvage surgery and surgery for metastases.

Surgery

  • Surgery is usually reserved for majority of patients.The feasibility of surgery depends on the stage of seminomsat diagnosis.[1][2][3]
  • The feasibility of surgery depends on the stage of seminoma at diagnosis.
  • Surgery is the mainstay of treatment for seminoma which include:[4][5][6][7]

Radical Inguinal Orchiectomy

  • Among patients who present with clinically advanced disease, radical orchiectomy is useful to remove the tumor prior to chemotherapy when possible.

Retroperitoneal Lymph Node Dissection

Salvage Surgery

  • Among patient who dose not response to chemotherapy after orchiectomy the surgery used to remove residual disease is called salvage surgery.[9][10]
  • Salvage surgery may include a bilateral RPLND.[11]

Surgery for Metastases

References

  1. Batool A, Karimi N, Wu XN, Chen SR, Liu YX (May 2019). “Testicular germ cell tumor: a comprehensive review”. Cell. Mol. Life Sci. 76 (9): 1713–1727. doi:10.1007/s00018-019-03022-7. PMID 30671589.
  2. Boujelbene, Noureddine; Cosinschi, Adrien; Boujelbene, Nadia; Khanfir, Kaouthar; Bhagwati, Shushila; Herrmann, Eveleyn; Mirimanoff, Rene-Olivier; Ozsahin, Mahmut; Zouhair, Abderrahim (2011). “Pure seminoma: A review and update”. Radiation Oncology. 6 (1). doi:10.1186/1748-717X-6-90. ISSN 1748-717X.
  3. Al-Salem, Ahmed H. (2014). “Testicular Tumors”: 505–511. doi:10.1007/978-3-319-06665-3_64.
  4. Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). “Pure seminoma: a review and update”. Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
  5. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V (October 2013). “Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol. 24 Suppl 6: vi125–32. doi:10.1093/annonc/mdt304. PMID 24078656.
  6. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J (December 2007). “Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors”. J. Clin. Oncol. 25 (35): 5603–8. doi:10.1200/JCO.2007.13.6283. PMID 17998544.
  7. 7.0 7.1 Lavery HJ, Bahnson RR, Sharp DS, Pohar KS (October 2009). “Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors”. Ther Adv Urol. 1 (4): 199–207. doi:10.1177/1756287209350315. PMC 3126061. PMID 21789067.
  8. Invalid <ref> tag; no text was provided for refs named pmid29487620
  9. Surgery for testicular cancer. Canadian cancer society 2016. http://www.cancer.ca/en/cancer-information/cancer-type/testicular/treatment/surgery/?region=on. Accessed on March 2, 2016
  10. Daneshmand S, Djaladat H, Nichols C (August 2011). “Management of residual mass in nonseminomatous germ cell tumors following chemotherapy”. Ther Adv Urol. 3 (4): 163–71. doi:10.1177/1756287211418721. PMC 3175700. PMID 21969846.
  11. Heidenreich A, Pfister D (August 2012). “Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice”. Ther Adv Urol. 4 (4): 187–205. doi:10.1177/1756287212443170. PMC 3398597. PMID 22852029.

Template:WH Template:WS

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH